SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the […]
Financial
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today provided a corporate update highlighting fundraising and clinical development milestones. These achievements have contributed to the continued successful development of its lead clinical program, while […]
BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors
MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors. Dr. Rietiker was most recently the Chief Executive Officer of LifeWatch AG, until it was acquired by BioTelemetry in August 2017. Prior to becoming CEO of […]
Amarin to Present at the Jefferies 2018 London Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 08, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a general company update at […]
MyoKardia Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018. “MyoKardia continues to make encouraging progress toward our mission of changing the […]
Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
LAVAL, Quebec, Nov. 07, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ: ACST – TSX-V: ACST) (the “Company” or “Acasti”), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that it will host […]
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer, will provide a corporate update at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November […]
Proteon Therapeutics Announces Third Quarter 2018 Financial Results
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended September 30, 2018, and recent business highlights. “We made excellent progress in […]
Correvio Reports Third Quarter 2018 Financial Results
VANCOUVER, Nov. 6, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV /TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its third quarter ended September 30, 2018 and commented on recent accomplishments and plans. “The past few months at Correvio have been highlighted by meaningful progress across a number of […]
Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast
VANCOUVER, Nov. 7, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and […]
